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OBJECTIVES: The choice of anticoagulant strategy in PCI affects the costs of treat-
ment for patients with AMI. Given the economic constraints of a fixed per-case
payment based on DRGs in Germany, anticoagulant strategy must not only offer
medical benefits for the patient but also be economically acceptable for hospitals.
Therefore the in-hospital costs of using different anticoagulants in a real-world
setting are highly relevant from a hospital perspective. Based on administrative
hospital data the purpose of this study was to determine the economic impact of
routinely used anticoagulant strategies in patients undergoing percutaneous cor-
onary intervention (PCI) for acute myocardial infarction (AMI) in Germany.
METHODS: We analyzed in a real-world scenario administrative routine data from
1409 patients undergoing PCI for AMI in two high-volume german PCI centers.
In-hospital costs of contemporary antithrombotic strategies, in detail 1) unfrac-
tionated heparin (UFH) monotherapy (n953); 2) UFH glycoprotein IIb/IIIa recep-
tor inhibitor (GPI; n337); or 3) bivalirudin (n119) were calculated based on the
observed resource utilization. RESULTS: Baseline characteristics were well bal-
anced and clinical outcomes were similar for all groups though not powered for
difference. Total length of stay (LOS) and time spent in ICU was lowest with bivali-
rudin. Therefore in-hospital costs were lowest with bivalirudin (UFH: 3807,2€ 
2235,98€; UFHGPI: 4643,15 4662,48€; bivalirudin: 3461,82€  1301,96€).
CONCLUSIONS: Compared with UFH monotherapy and UFH  GPI, the use of bi-
valirudin among patients undergoing PCI for AMI in Germany results in a shorter
ICU and total LOS and appears to reduce in-hospital costs.
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OBJECTIVES: Identify treatment patterns and cost for the prophylaxis of venous
thromboembolism (VTEp) in patients undergoing total hip o knee replacement
(THR oTKR) from the public payer perspective in Mexico. In addition, this study
assesses VTE incidence rate and adverse events commonly with prophylaxis
treatment. METHODS: A retrospective cohort in four public hospitals was con-
ducted, recruiting 650 patients undergoing THR or TKR from September 2011 to
February 2012. Through medical records review, demographic, clinical and re-
source utilization data was gathered over hospitalization period and ambulatory
monitoring follow-up for 3 months. Patients were categorized according to VTEp
treatment, incidence of VTE (deep vein thrombosis (DVP) and pulmonary embolism
(PE)), and associated adverse events (major or minor bleeds). Direct medical cost
(lenght of hospital stay, and ambulatory care) associated with each therapy were
calculated and expressed in US dollars (USD) at exchange rate of 13.72 Mexican
pesos/USD (June 2012). Statistical differences were identified by Kuskal-Wallis test.
RESULTS: A total of 650 patiens were included, with an average age of 66 / 11
years, 55% men. With TKR 57% and THR 43%, were 66.5 had one co-morbidity, being
the most frequent systemic hypertension (51%). VTEp was given to 95.3% of pa-
tients. The prescribed drugs were: enoxoparin (86%), nadroparin (6.4%), unfraction-
ated heparin (0.8%), rivaroxaban (6.3%), dabigatran (0.5%). DVP incidence resulted
in 0.3%, major bleeds in 0.2%, and minor bleeds in 0.6%. Mean direct medical costs
for each agent were: enoxoparin 4.450 USD (2.458-14.733); nadroparin 3.016 USD
(2.792-3.639); unfractionated heparin 4.603 USD (3.675-5.312); rivaroxaban 4.427
USD (3.626-6.885); dabigatran 4.347 USD (4.166-4.468); and without VTEp 5.077 USD
(2.801-13.235) (p0.05). CONCLUSIONS: VTEp therapies are common and safe in
mexican patients. Incidence of VTE is low, while higher costs were observed in
patients with non-prophylaxis treatment.
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OBJECTIVES: To study the medicinal treatment of hypertension and its impact on
the cost of therapy. The study is developed from the point of view of the health
insurance institution and patients. METHODS: Prospective observational study of
prescribing patterns and cost of pharmacotherapy. Patients‘ demographics, clini-
cal data (blood pressure range), pharmacotherapy costs of hypertension were col-
lected and proceeded. RESULTS: A total of 5000 patients participated in the study.
Preliminary results for the first 1000 patients are presented. The average age was 64
years (57% female); 88% were living in the cities, and 72% were hypertonic since 1 to
5 years. On total 47 medicines’ INN were prescribed in all prescriptions. Most fre-
quently ACE inhibitors were found prescribed in 421 of all prescriptions, followed
by diuretics in 378 prescriptions. 7 INN of antihypertensive medicines were pre-
scribed in 47% of prescrptions. The adequate control of blood pressure was reached
only from 40% of observed patients, but 60% declare satisfaction of their pharma-
cotherapy in contradiction with the insufficient control. The total cost of the phar-
macotherapy of 1000 patients for one month was 10679.53 €, and out of them
2698.42 € have been reimbursed. Thus the average monthly cost per patient was
found to be 10.67 €. On mono therapy were 23% of the patients, 41% on dual ther-
apy, and 36 % on politherapy. Their respective monthly cost per patient was – 1.25
€ (23% reimbursed) for monotherapy, 8.7 € (25% reimbursed) for dual therapy, 15.8
€ (26% reimbursed) for polytherapy. CONCLUSIONS: The cost per patients is rela-
tive lower but the main burden is carried out by the patients. With the increase in
the complexity of pharmacotherapy the cost per patients logically increases but
reimbursement level remains almost unchanged.
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OBJECTIVES: Cost-effectiveness analysis performed in 2010 showed that the use of
rivaroxaban for the prevention of deep vein thrombosis (DVT) and pulmonary em-
bolism (PE) after total knee replacement (TKR) is dominant technology (Vorobiev P.
et al. Value in Health, 2011). Objective of this study was to evaluate the cost-
effectiveness of rivaroxaban compared to dabigatran and enoxaparin for the pro-
phylaxis of venous thromboembolism in patients after TKR taking into account the
recent drug price changes. METHODS: Cost-effectiveness analysis of rivaroxaban
versus dabigatran and enoxaparin to prevent venous thromboembolism after TKR
was done in 2010. A decision-tree model of different regimens for thromboprophy-
laxis after THR was adopted from the model, developed by McCullagh et al. (2009).
Total costs and incremental cost-effectiveness ratios (ICERs) were calculated. In
2012 the price of rivaroxaban and dabigatran reduced by 63.8% and 34.6% respec-
tively, while the price of enoxaparin increased by 6.8%. RESULTS: The total cost of
rivaroxaban prophylaxis was 4678 €, enoxaparin – 4946 €, dabigatran – 4980 €. To
prevent one event of DVT with rivaroxaban the ICER is lower by 2553 € than dab-
igatran and by 2593 € than enoxaparin. To prevent one event of PE with rivaroxaban
the ICER is lower by 268 € than dabigatran and by 307 € than enoxaparin.
CONCLUSIONS: Sensitivity analysis using new prices confirmed that the use of
rivaroxaban for prevention of venous thromboembolism after TKR remains the
dominant technology compared to dabigatran and enpxaparin.
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OBJECTIVES: Despite of higher cost of deep vein thrombosis (DVT) and pulmonary
embolism (PE) prophylaxis after total hip replacement (THR) with rivaroxaban
compared to enoxaparin and dabigatran, it was more effective than two other
alternatives with acceptable incremental cost-effectiveness ratios (ICERs) (Voro-
biev P. et al. Value in Health, 2011). Objective of this study was to evaluate the
cost-effectiveness of rivaroxaban compared to dabigatran and enoxaparin for the
prophylaxis of venous thromboembolism in patients undergoing elective THR, tak-
ing into account the drug price changes. METHODS: Cost-effectiveness analysis of
rivaroxaban versus dabigatran and enoxaparin to prevent venous thromboembo-
lism after THR was carried out in 2010. A decision-tree model of the choice of
thromboprophylaxis regimens was adopted from the model developed by McCul-
lagh et al. (2009). Total costs and ICERs were calculated. In 2012 the price of rivar-
oxaban and dabigatran decreased by 63.8% and 34.6% respectively, while the price
of enoxaparin increased by 6.8% (IMS). RESULTS: Total costs for the prevention of
venous thromboembolism after THR were as follow: rivaroxaban – 6102 € (5221 € in
2010); dabigatran – 6155 € (5156 € in 2010); enoxaparin – 6154 € (5094 € in 2010). To
prevent one event of DVT with rivaroxaban the ICER is lower by 244 € than dabiga-
tran and by 502 € than enoxaparin. To prevent one event of PE with rivaroxaban the
ICER is lower by 72 € than dabigatran and by 77 € than enoxaparin. CONCLUSIONS:
Sensitivity analysis demonstrated that the use of rivaroxaban for the prevention of
venous thromboembolism after THR compared to dabigatran and enoxaparin is
the dominant technology.
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OBJECTIVES: Whether it is possible to ground health technology assessment on
egalitarian social justice theory is an ongoing debate. This study aims to contribute
to answer this question as it is focussed on concrete application of equivalent
income approach that has been developed by M. Fleurbaey (2007) and aiming to
include inequality aversion in cost/benefit analysis. The objective is to prove its
feasibility in the context of public decision making. For this first application case, it
has been chosen to focus on the economic assessment of antihypertensive treat-
ments for patients with essential hypertension. METHODS: The method is based
on the comparison of two social welfare functions: social welfare function in terms
of individuals’ equivalent incomes when antihypertensive treatments are pre-
scribed in primary prevention (SWA) and social welfare function in terms of indi-
viduals’ equivalent incomes when there is no antihypertensive treatment in pri-
mary prevention (SWB) . If SWA SWB  0, then it would be considered that
antihypertensive treatments in primary prevention are welfare improving com-
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